CCL2 and neoplasm: Another study in BRAF V600E mouse melanoma transplants and in de novo melanomas demonstrated that BRAF inhibitor downregulated tumor expression of chemokine (C-C motif) ligand 2 (CCL2), and resulted in a robust increase in CD8+ T/FoxP3+CD4+ T cell ratio and natural killer (NK) cells [41].